Canterbury DHB

Context

July 2020

don't forget to update the issue and next review variables!!!

Changes in this release

Topic or section

Brief description

Reviewer

CLL, HCL, & LGL Leukaemia

We've updated the Ibrutinib subsection of Relapsed or Refractory Patients.

Andrew Butler

About this Canterbury DHB document (772358):

Document Owner:

Not assigned (see Who's Who)

Last Reviewed:

Next Review:

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 772358